Molecular signatures for use in diagnosis and response to treatment analysis of autoimmune diseases
AssigneesUcb Biopharma Srl, Biogen MA Inc.
InventorsGeoffrey Johnston, Carrie G. Wager, Huo Li, Ann Ranger
Life of this patent
Estimating the term…
Abstract
The present invention relates to molecular signatures that can be used to identify patients diagnosed with an autoimmune disease, in particular with systemic lupus erythematosus for treatment with a CD40 or CD40L antagonist such as anti-CD40 antibody, anti-CD40L antibody or a binding fragment thereof. The signatures can also be used to monitor target engagement and response to treatment.
Claims18
A method for monitoring treatment of systemic lupus erythematosus (SLE) or lupus nephritis in a patient with a CD40L antagonist comprising administering said CD40L antagonist to said patient and, subsequently:
- a) determining the expression levels of IGHA1 and IGLC2 in a nucleic acid sample obtained from said patient,
- b) determining the expression levels for IGHA1 and IGLC2 in a control nucleic acid sample, and
- c) administering said CD40L antagonist to a patient in which the expression levels of IGHA1 and IGLC2 are transiently decreased relative to the expression levels of IGHA1 and IGLC2 in said control sample, wherein:
- said CD40L antagonist is an anti-CD40L antibody or fragment thereof comprising a light chain variable region comprising a light chain CDR1 comprising SEQ ID NO:
- 47, a light chain CDR2 comprising SEQ ID NO:
- 48, and a light chain CDR3 comprising SEQ ID NO:
- 49 and a heavy chain variable region comprising a heavy chain CDR1 comprising SEQ ID NO:
- 50, a heavy chain CDR2 comprising SEQ ID NO:
- 51, and a heavy chain CDR3 comprising SEQ ID NO:
- 52.
A method of identifying and treating a patient suffering from systemic lupus erythematosus (SLE) or lupus nephritis with a CD40L antagonist comprising at least the steps of:
- a) determining the expression level of IGHA1 and IGLC2 in a nucleic acid sample obtained from a patient which has been diagnosed with said autoimmune disease,
- b) determining the expression level of IGHA1 and IGLC2 in a control nucleic acid sample, and
- c) treating a patient having an increased expression level of IGHA1 and IGLC2 relative to the expression level of IGHA1 and IGLC2 in the control sample with a CD40L antagonist, wherein:
- said CD40L antagonist is an anti-CD40L antibody or fragment thereof comprising a light chain variable region comprising a light chain CDR1 comprising SEQ ID NO:
- 47, a light chain CDR2 comprising SEQ ID NO:
- 48, and a light chain CDR3 comprising SEQ ID NO:
- 49 and a heavy chain variable region comprising a heavy chain CDR1 comprising SEQ ID NO:
- 50, a heavy chain CDR2 comprising SEQ ID NO:
- 51, and a heavy chain CDR3 comprising SEQ ID NO:
- 52.
Dependencies are inferred from the claim text.